The	O
idea	O
that	O
the	O
customer	O
is	O
always	O
right	O
is	O
gospel	O
in	O
most	O
areas	O
of	O
business	O
.	O
	
Most	O
,	O
you	O
might	O
think	O
,	O
except	O
the	O
business	O
of	O
making	O
drugs	B-KP
and	O
vaccines	B-KP
.	O
	
Not	O
so	O
.	O
	
The	O
cautionary	O
tale	O
of	O
the	O
Lyme-disease	B-KP
vaccine	I-KP
is	O
a	O
good	O
example	O
of	O
how	O
consumer	O
power	O
can	O
override	O
science	O
.	O
	
Lyme	B-KP
disease	I-KP
is	O
a	O
debilitating	O
infection	B-KP
spread	O
by	O
bites	O
from	O
ticks	O
.	O
	
Found	O
mainly	O
in	O
the	O
United	O
States	O
and	O
Europe	O
,	O
its	O
prevalence	O
is	O
increasing	O
as	O
civilization	O
encroaches	O
on	O
forested	O
areas	O
-	O
home	O
to	O
the	O
deer	O
on	O
which	O
the	O
ticks	O
feed	O
.	O
	
A	O
vaccine	B-KP
is	O
badly	O
needed	O
to	O
contain	O
the	O
disease	O
,	O
but	O
the	O
one	O
jab	O
available	O
was	O
pulled	O
from	O
the	O
market	O
after	O
complaints	O
from	O
a	O
group	O
of	O
patients	O
damaged	O
its	O
reputation	O
.	O
	
Now	O
,	O
a	O
similar	O
vaccine	B-KP
is	O
set	O
to	O
emerge	O
,	O
but	O
some	O
say	O
it	O
has	O
been	O
tweaked	O
in	O
a	O
way	O
that	O
confers	O
no	O
obvious	O
scientific	O
benefit	O
.	O
	
Lyme	B-KP
disease	I-KP
made	O
a	O
meteoric	O
entry	O
into	O
medical	O
and	O
public	O
consciousness	O
30	O
years	O
ago	O
,	O
when	O
Allen	O
Steere	O
,	O
a	O
rheumatologist	O
now	O
at	O
Massachusetts	O
General	O
Hospital	O
in	O
Boston	O
,	O
described	O
an	O
outbreak	O
of	O
a	O
mysterious	O
illness	O
in	O
Lyme	O
,	O
Connecticut	O
.	O
	
The	O
disease	O
he	O
identified	O
was	O
caused	O
by	O
a	O
spirochete	B-KP
,	O
a	O
spiral-shaped	B-KP
bacterium	I-KP
called	O
Borrelia	B-KP
burgdorferi	I-KP
.	O
	
It	O
is	O
rarely	O
fatal	O
,	O
but	O
acute	O
infection	O
results	O
in	O
a	O
range	O
of	O
unpleasant	O
and	O
debilitating	O
symptoms	O
,	O
including	O
flu-like	O
effects	O
,	O
a	O
bullseye	B-KP
rash	I-KP
and	O
neurological	B-KP
problems	I-KP
such	O
as	O
facial	B-KP
palsy	I-KP
.	O
	
After	O
several	O
weeks	O
without	O
treatment	O
,	O
some	O
patients	O
go	O
on	O
to	O
develop	O
joint	B-KP
pain	I-KP
or	O
arthritis	B-KP
.	O
	
If	O
left	O
untreated	O
,	O
it	O
can	O
last	O
for	O
years	O
,	O
but	O
even	O
then	O
will	O
usually	O
respond	O
to	O
antibiotics	B-KP
.	O
	
In	O
a	O
small	O
subset	O
of	O
patients	O
,	O
however	O
,	O
the	O
joint	O
pain	O
and	O
swelling	O
do	O
not	O
respond	O
-	O
the	O
condition	O
is	O
known	O
as	O
treatment-resistant	B-KP
Lyme	I-KP
arthritis	I-KP
.	O
	
It	O
was	O
arguments	O
about	O
the	O
long-term	O
persistence	O
of	O
Lyme	B-KP
disease	I-KP
that	O
triggered	O
the	O
first	O
'	O
Lyme	O
scandal	O
'	O
.	O
	
In	O
the	O
1990s	O
,	O
Steere	O
was	O
hounded	O
by	O
patients	O
who	O
claimed	O
to	O
be	O
suffering	O
from	O
a	O
chronic	O
form	O
of	O
Lyme	B-KP
disease	I-KP
that	O
left	O
them	O
persistently	O
exhausted	O
.	O
	
Steere	O
insisted	O
that	O
they	O
had	O
been	O
misdiagnosed	O
.	O
	
Although	O
the	O
patients	O
had	O
antibodies	B-KP
to	O
Lyme	B-KP
disease	I-KP
,	O
indicating	O
that	O
they	O
had	O
at	O
one	O
time	O
been	O
exposed	O
to	O
Borrelia	B-KP
,	O
Steere	O
maintained	O
that	O
their	O
range	O
of	O
vague	O
symptoms	O
did	O
not	O
correlate	O
with	O
the	O
true	O
course	O
of	O
the	O
disease	O
.	O
	
He	O
says	O
he	O
wanted	O
to	O
save	O
people	O
from	O
unnecessary	O
antibiotic	B-KP
treatment	I-KP
,	O
but	O
instead	O
found	O
himself	O
under	O
protection	O
of	O
security	O
guards	O
,	O
and	O
dealing	O
with	O
hate	O
mail	O
and	O
even	O
death	O
threats	O
.	O
	
﻿In	O
recent	O
years	O
,	O
species	O
of	O
Borrelia	B-KP
have	O
been	O
recognized	O
as	O
the	O
etiologic	B-KP
agents	I-KP
of	O
several	O
apparently	O
diverse	O
diseases	O
,	O
including	O
erythema	B-KP
chronicum	I-KP
migrans	I-KP
(	O
ECM	B-KP
)	O
;	O
Lyme	B-KP
disease	I-KP
(	O
LD	B-KP
)	O
;	O
acrodermatitis	B-KP
chronica	I-KP
atrophicans	I-KP
(	O
ACA	B-KP
)	O
;	O
lymphadenosis	B-KP
benigna	I-KP
cutis	I-KP
(	O
LBC	B-KP
)	O
,	O
originally	O
called	O
Spiegler-Fendt	B-KP
sarcoid	I-KP
;	O
and	O
possibly	O
some	O
types	O
of	O
morphea	B-KP
,	O
lichen	B-KP
sclerosus	I-KP
et	I-KP
atrophicus	I-KP
(	O
LSA	B-KP
)	O
,	O
progressive	B-KP
facial	I-KP
hemiatrophy	I-KP
of	I-KP
Parry-Romberg	I-KP
(	O
PFH	B-KP
)	O
,	O
benign	B-KP
lymphocytic	I-KP
infiltrate	I-KP
of	I-KP
the	I-KP
skin	I-KP
(	O
Jessner-Kanof	O
)	O
(	O
BLI	B-KP
)	O
,	O
and	O
Shulman	B-KP
syndrome	I-KP
(	O
eosinophilic	B-KP
fasciitis	I-KP
)	O
.	O
	
Lyme	B-KP
disease	I-KP
was	O
reviewed	O
in	O
Part	O
I	O
of	O
this	O
series	O
.	O
[	O
1	O
]	O
ACA	B-KP
,	O
LBC	B-KP
,	O
LSA	B-KP
,	O
PFH	B-KP
,	O
BLI	B-KP
,	O
and	O
Shulman	B-KP
syndrome	I-KP
have	O
been	O
linked	O
in	O
varying	O
degrees	O
with	O
borreliae	B-KP
and	O
are	O
the	O
subject	O
of	O
this	O
review	O
.	O
	
﻿Lyme	B-KP
disease	I-KP
can	O
be	O
classified	O
using	O
the	O
terminology	O
of	O
syphilis	B-KP
.	O
	
In	O
this	O
series	O
of	O
95	O
cases	O
from	O
the	O
upper	O
midwest	O
,	O
early	O
cases	O
,	O
defined	O
as	O
an	O
illness	O
of	O
<2	O
months	O
,	O
were	O
more	O
likely	O
to	O
have	O
lived	O
in	O
or	O
recently	O
visited	O
a	O
highly	O
endemic	B-KP
area	I-KP
.	O
	
Unlike	O
late	O
cases	O
,	O
early	O
cases	O
presented	O
entirely	O
in	O
the	O
nonwinter	O
months	O
(	O
p	O
<	O
.	O
001	O
)	O
.	O
	
Early	O
disease	O
was	O
further	O
subdivided	O
into	O
primary	O
and	O
secondary	O
disease	O
.	O
	
Ninety	O
percent	O
of	O
primary	O
and	O
43	O
%	O
of	O
secondary	O
cases	O
had	O
erythema	B-KP
migrans	I-KP
,	O
while	O
no	O
late	O
cases	O
had	O
active	O
erythema	B-KP
migrans	I-KP
(	O
p	O
<	O
.	O
001	O
)	O
.	O
	
Clinical	B-KP
manifestations	I-KP
of	I-KP
nonspecific	I-KP
inflammation	I-KP
,	O
except	O
for	O
arthralgia	B-KP
,	O
were	O
more	O
common	O
in	O
early	O
than	O
late	O
disease	O
(	O
p	O
<	O
.	O
01	O
)	O
.	O
	
In	O
secondary	O
cases	O
,	O
monoarticular	B-KP
arthritis	I-KP
was	O
slightly	O
more	O
common	O
than	O
polyarticular	B-KP
arthritis	I-KP
,	O
with	O
the	O
reverse	O
occurring	O
in	O
late	O
disease	O
(	O
p	O
<	O
.	O
05	O
)	O
.	O
	
Indirect	B-KP
fluorescent	I-KP
antibody	I-KP
testing	I-KP
revealed	O
a	O
ratio	O
of	O
IgM	B-KP
to	O
IgG	B-KP
antibodies	I-KP
to	O
be	O
helpful	O
in	O
distinguishing	O
early	O
from	O
late	O
disease	O
.	O
	
Antibacterial	B-KP
therapy	I-KP
in	O
early	O
,	O
primary	O
cases	O
caused	O
Jarisch-Herxheimer	B-KP
reaction	O
7	O
%	O
of	O
the	O
time	O
.	O
	
Despite	O
longer	O
and	O
more	O
frequent	O
parenteral	O
therapy	O
,	O
late	O
Lyme	B-KP
disease	I-KP
frequently	O
required	O
retreatment	O
,	O
owing	O
to	O
poor	O
clinical	O
response	O
(	O
p	O
<	O
.	O
05	O
)	O
.	O
	
﻿For	O
patients	O
in	O
category	O
1	O
,	O
proper	O
care	O
needs	O
to	O
be	O
practiced	O
when	O
removing	O
ticks	O
,	O
especially	O
the	O
Ixodes	B-KP
genus	I-KP
,	O
from	O
the	O
skin	B-KP
.	O
	
It	O
is	O
often	O
difficult	O
to	O
definitively	O
identify	O
a	O
tick	O
as	O
I	B-KP
.	I-KP
scapularis	I-KP
in	O
the	O
ED	B-KP
;	O
however	O
,	O
in	O
endemic	B-KP
areas	I-KP
with	O
high	O
LD	B-KP
prevalence	O
or	O
in	O
cases	O
where	O
there	O
is	O
high	O
clinical	O
suspicion	O
for	O
tick	O
exposure	O
,	O
emergency	O
physicians	O
should	O
evaluate	O
and	O
treat	O
patients	O
with	O
the	O
assumption	O
that	O
the	O
tick	O
is	O
I	B-KP
.	I-KP
scapularis	I-KP
and	O
consider	O
sending	O
the	O
tick	O
for	O
pathology	B-KP
identification	I-KP
.	O
	
Ixodes	B-KP
ticks	I-KP
cement	O
their	O
mouth	O
parts	O
into	O
the	O
skin	O
with	O
secretions	O
from	O
their	O
salivary	O
glands	O
and	O
have	O
specialized	O
structures	O
for	O
holding	O
them	O
in	O
the	O
skin	O
while	O
the	O
tick	O
feeds	O
.	O
	
Attached	O
ticks	O
should	O
be	O
removed	O
with	O
fine-tip	O
forceps	O
.	O
	
Any	O
portion	O
of	O
the	O
mouth	O
parts	O
of	O
the	O
tick	O
still	O
embedded	O
in	O
the	O
skin	O
need	O
not	O
be	O
removed	O
and	O
only	O
disinfected	O
,	O
for	O
there	O
is	O
no	O
risk	O
of	O
LD	B-KP
and	O
the	O
removal	O
can	O
cause	O
unnecessary	O
tissue	O
damage	O
.	O
	
Use	O
of	O
hot	O
objects	O
,	O
such	O
as	O
matches	O
,	O
is	O
contraindicated	O
and	O
may	O
induce	O
regurgitation	O
and	O
cause	O
infected	O
fluids	O
to	O
enter	O
the	O
wound	O
(	O
44	O
)	O
.	O
	
﻿Serum	O
samples	O
were	O
tested	O
for	O
evidence	O
of	O
infection	O
by	O
the	O
agents	O
of	O
Lyme	B-KP
disease	I-KP
(	O
B	B-KP
.	I-KP
burgdorferi	I-KP
)	O
,	O
human	B-KP
monocytic	I-KP
ehrlichiosis	I-KP
(	O
Ehrlichia	B-KP
chaffeensis	I-KP
)	O
,	O
human	B-KP
granulocytic	I-KP
ehrlichiosis	I-KP
(	O
Ehrlichia	B-KP
phagocytophila	I-KP
)	O
,	O
Rocky	B-KP
Mountain	I-KP
spotted	I-KP
fever	I-KP
(	O
Rickettsia	B-KP
rickettsii	I-KP
)	O
,	O
murine	B-KP
typhus	I-KP
(	O
Rickettsia	B-KP
typhi	I-KP
)	O
,	O
Q	B-KP
fever	I-KP
(	O
Coxiella	B-KP
burneti	I-KP
)	O
,	O
tularaemia	B-KP
(	O
Francisella	B-KP
tularensis	I-KP
)	O
and	O
babesiosis	B-KP
(	O
Babesia	B-KP
microti	I-KP
)	O
.	O
	
IgG	B-KP
antibodies	I-KP
against	O
antigens	B-KP
of	I-KP
E	I-KP
.	I-KP
chaffeensis	I-KP
,	O
E	B-KP
.	I-KP
phagocytophila	I-KP
,	O
R	B-KP
.	I-KP
rickettsii	I-KP
,	O
R	B-KP
.	I-KP
typhi	I-KP
,	O
C	B-KP
.	I-KP
burneti	I-KP
,	O
and	O
B	B-KP
.	I-KP
microti	I-KP
were	O
tested	O
by	O
indirect	B-KP
fluorescent	I-KP
antibody	I-KP
assays	I-KP
(	O
IFA	B-KP
)	O
,	O
as	O
previously	O
described	O
(11–14).	O
	
The	O
serum	O
samples	O
were	O
screened	O
against	O
F	B-KP
.	I-KP
tularensis	I-KP
by	O
an	O
agglutination	B-KP
assay	I-KP
,	O
according	O
to	O
the	O
manufacturer's	O
recommendations	O
(	O
Difco	O
Laboratories	O
,	O
Detroit	O
,	O
MI	O
,	O
USA	O
)	O
.	O
	
IgG	B-KP
antibodies	I-KP
against	O
the	O
Lyme	B-KP
disease	I-KP
spirochaete	B-KP
were	O
initially	O
detected	O
by	O
enzyme-linked	B-KP
immunosorbent	I-KP
assay	I-KP
(	O
ELISA	B-KP
)	O
using	O
antigens	B-KP
of	O
the	O
N40	O
strain	O
of	O
B	B-KP
.	I-KP
burgdorferi	I-KP
sensu	O
stricto	O
(	O
15	O
)	O
.	O
	
Briefly	O
,	O
low-passage	O
wildtype	O
N40	O
was	O
harvested	O
at	O
log-phase	O
growth	O
,	O
washed	O
three	O
times	O
in	O
Hanks	B-KP
'	I-KP
balanced	I-KP
salt	I-KP
solution	I-KP
(	O
HBSS	B-KP
)	O
,	O
and	O
resuspended	O
in	O
20	O
times	O
the	O
original	O
culture	O
volume	O
in	O
HBSS	B-KP
.	O
The	O
washed	O
spirochaetes	B-KP
were	O
sonicated	O
on	O
ice	O
until	O
darkfield	B-KP
microscopy	I-KP
indicated	O
that	O
>85%	O
of	O
the	O
organisms	O
had	O
been	O
disrupted	O
.	O
	
After	O
centrifugation	O
to	O
remove	O
fragments	O
and	O
whole	O
spirochaetes	B-KP
,	O
the	O
soluble	O
extract	O
was	O
aliquoted	O
and	O
stored	O
at	O
–	O
20C	O
.	O
Microtitre	O
plates	O
(	O
Immulon	O
4	O
,	O
Dynex	O
,	O
Chantilly	O
,	O
VA	O
,	O
USA	O
)	O
were	O
coated	O
with	O
250	O
mg	O
of	O
antigen	B-KP
per	O
well	O
and	O
allowed	O
to	O
dry	O
.	O
	
The	O
plates	O
were	O
blocked	O
with	O
5	O
%	O
donor	O
horse	O
serum	O
,	O
1	O
%	O
dextran	O
sulfate	O
in	O
PBS-Tween	O
20	O
.	O
	
Sera	O
were	O
diluted	O
in	O
this	O
blocking	O
buffer	O
at	O
1:100,	O
added	O
to	O
wells	O
in	O
triplicate	O
,	O
and	O
incubated	O
for	O
1	O
hour	O
.	O
	
Bound	O
antibody	B-KP
was	O
detected	O
by	O
the	O
addition	O
of	O
alkaline	B-KP
phosphatase-conjugated	I-KP
goat	I-KP
antihuman	I-KP
IgG	I-KP
(	O
Kirkegaard	O
&	O
Perry	O
Laboratories	O
,	O
Gaithersburg	O
,	O
MD	O
,	O
USA	O
)	O
,	O
as	O
recommended	O
by	O
the	O
manufacturer	O
.	O
	
A	O
p-nitrophenyl	B-KP
phosphate	I-KP
substrate	I-KP
in	I-KP
diethanolamine	I-KP
buffer	I-KP
was	O
used	O
to	O
visualize	O
bound	O
secondary	B-KP
antibody	I-KP
when	O
the	O
reactions	O
were	O
terminated	O
at	O
30	O
minutes	O
,	O
and	O
read	O
promptly	O
at	O
l	O
=	O
405	O
nm	O
.	O
	
Negative	O
control	O
sera	O
(	O
n	O
=	O
6	O
)	O
,	O
taken	O
from	O
laboratory	O
staff	O
members	O
with	O
no	O
history	O
of	O
Lyme	B-KP
disease	I-KP
,	O
were	O
analysed	O
on	O
each	O
plate	O
.	O
	
A	O
serum	O
sample	O
was	O
considered	O
reactive	O
if	O
its	O
mean	O
absorbance	O
exceeded	O
3	O
standard	O
deviations	O
of	O
the	O
mean	O
of	O
the	O
18	O
(	O
6	O
x	O
3	O
)	O
negative	O
control	O
wells	O
,	O
calculated	O
for	O
each	O
microtitre	O
plate	O
.	O
	
﻿Lyme	B-KP
arthritis	I-KP
was	O
originally	O
recognized	O
because	O
of	O
an	O
outbreak	O
of	O
monoarticular	B-KP
and	I-KP
oligoarticular	I-KP
arthritis	I-KP
in	O
children	O
in	O
Lyme	O
,	O
Connecticut	O
in	O
the	O
1970s	O
.	O
[	O
1	O
]	O
It	O
then	O
became	O
apparent	O
that	O
Lyme	B-KP
disease	I-KP
was	O
a	O
complex	O
multisystem	O
illness	O
affecting	O
primarily	O
skin	B-KP
,	O
nervous	B-KP
system	I-KP
,	O
heart	B-KP
or	O
joints	B-KP
.	O
[	O
2	O
]	O
Prior	O
to	O
the	O
use	O
of	O
antibiotic	B-KP
therapy	I-KP
for	O
treatment	O
of	O
the	O
disease	O
,	O
about	O
60	O
%	O
of	O
untreated	O
patients	O
developed	O
Lyme	B-KP
arthritis	I-KP
,	O
a	O
late	O
disease	O
manifestation	O
.	O
[	O
3	O
]	O
In	O
recent	O
years	O
,	O
over	O
30,000	O
cases	O
of	O
Lyme	B-KP
disease	I-KP
have	O
been	O
reported	O
annually	O
to	O
the	O
Centers	O
for	O
Disease	O
Control	O
and	O
Prevention	O
(	O
CDC	O
)	O
,	O
and	O
in	O
a	O
third	O
of	O
reported	O
cases	O
,	O
arthritis	B-KP
was	O
a	O
manifestation	O
of	O
the	O
disease	O
.	O
[	O
4	O
]	O
However	O
,	O
recent	O
CDC	O
estimates	O
suggest	O
the	O
actual	O
number	O
of	O
infections	O
with	O
the	O
Lyme	B-KP
disease	I-KP
spirochete	I-KP
may	O
be	O
10-fold	O
higher	O
.	O
[	O
5	O
]	O
The	O
infection	O
is	O
transmitted	O
primarily	O
by	O
nymphal	B-KP
Ixodes	I-KP
scapularis	I-KP
ticks	I-KP
,	O
which	O
quest	O
in	O
the	O
late	O
spring	O
and	O
early	O
summer	O
.	O
[	O
6	O
]	O
However	O
,	O
Lyme	B-KP
arthritis	I-KP
can	O
present	O
at	O
any	O
time	O
of	O
the	O
year	O
.	O
	
The	O
majority	O
of	O
cases	O
occur	O
in	O
the	O
northeastern	O
United	O
States	O
,	O
from	O
Maine	O
to	O
Virginia	O
.	O
[	O
5	O
]	O
Other	O
affected	O
areas	O
in	O
the	O
U.S.	O
include	O
the	O
northern	O
mid-Western	O
states	O
of	O
Minnesota	O
,	O
Wisconsin	O
,	O
and	O
Michigan	O
;	O
and	O
the	O
West	O
coast	O
in	O
northern	O
California	O
.	O
	
In	O
the	O
United	O
States	O
,	O
Borrelia	B-KP
burgdorferi	I-KP
is	O
the	O
sole	O
cause	O
of	O
the	O
disease	O
,	O
but	O
subtypes	O
of	O
B	B-KP
.	I-KP
burgdorferi	I-KP
differ	O
in	O
pathogenicity	O
.	O
[7,8]	O
OspC	B-KP
type	I-KP
A	I-KP
(	O
RST1	B-KP
)	O
strains	O
,	O
which	O
account	O
for	O
30-50	O
%	O
of	O
the	O
infection	O
in	O
the	O
northeastern	O
US	O
,	O
[7,8]	O
but	O
only	O
3	O
%	O
in	O
mid-Western	O
states	O
,	O
[	O
9	O
]	O
are	O
particularly	O
virulent	O
and	O
arthritogenic	O
.	O
	
These	O
strains	O
are	O
thought	O
to	O
have	O
played	O
an	O
important	O
role	O
in	O
the	O
emergence	O
of	O
the	O
Lyme	B-KP
disease	I-KP
epidemic	I-KP
in	O
the	O
northeastern	O
U.S.	O
in	O
the	O
late	O
20th	O
century	O
.	O
[	O
10	O
]	O
﻿In	O
addition	O
to	O
serologic	B-KP
testing	I-KP
,	O
clinical	O
features	O
may	O
distinguish	O
Lyme	B-KP
arthritis	I-KP
from	O
other	O
arthritides	O
.	O
	
A	O
common	O
concern	O
is	O
mechanical	O
injury	O
in	O
an	O
active	O
individual	O
,	O
and	O
therefore	O
,	O
orthopedists	O
are	O
often	O
the	O
first	O
specialist	O
to	O
see	O
a	O
patient	O
with	O
Lyme	B-KP
arthritis	I-KP
.	O
	
However	O
,	O
the	O
clinical	O
picture	O
of	O
Lyme	B-KP
arthritis	I-KP
is	O
most	O
like	O
reactive	B-KP
arthritis	I-KP
in	O
adults	O
or	O
pauciarticular	B-KP
juvenile	I-KP
idiopathic	I-KP
arthritis	I-KP
in	O
children	O
,	O
and	O
serologic	B-KP
testing	I-KP
is	O
essential	O
to	O
distinguish	O
Lyme	B-KP
arthritis	I-KP
from	O
these	O
entities	O
.	O
	
Children	O
may	O
have	O
a	O
more	O
acute	O
presentation	O
,	O
with	O
higher	O
synovial	B-KP
WBC	I-KP
counts	I-KP
which	O
may	O
suggest	O
a	O
diagnosis	O
of	O
acute	B-KP
septic	I-KP
arthritis	I-KP
.	O
[	O
22-24	O
]	O
However	O
,	O
Lyme	B-KP
arthritis	I-KP
typically	O
causes	O
only	O
minimal	O
pain	O
with	O
passive	O
range	O
of	O
motion	O
,	O
and	O
involvement	O
of	O
more	O
than	O
one	O
joint	O
(	O
currently	O
or	O
by	O
history	O
)	O
may	O
help	O
to	O
distinguish	O
Lyme	B-KP
arthritis	I-KP
from	O
septic	B-KP
bacterial	I-KP
arthritis	I-KP
.	O
[	O
22-24	O
]	O
Lyme	B-KP
arthritis	I-KP
rarely	O
,	O
if	O
ever	O
,	O
causes	O
chronic	O
,	O
symmetrical	B-KP
polyarthritis	I-KP
,	O
which	O
helps	O
to	O
distinguish	O
Lyme	B-KP
arthritis	I-KP
from	O
rheumatoid	B-KP
arthritis	I-KP
.	O
	
Fibromyalgia	B-KP
is	O
sometimes	O
misdiagnosed	O
as	O
Lyme	B-KP
disease	I-KP
,	O
but	O
patients	O
with	O
fibromyalgia	B-KP
generally	O
have	O
diffuse	O
pain	O
,	O
and	O
they	O
lack	O
objective	O
evidence	O
of	O
joint	O
inflammation	O
.	O
	
Other	O
inflammatory	B-KP
arthritides	I-KP
,	O
such	O
as	O
rheumatoid	B-KP
arthritis	I-KP
,	O
reactive	B-KP
arthritis	I-KP
,	O
or	O
psoriatic	B-KP
arthritis	I-KP
may	O
develop	O
within	O
months	O
after	O
Lyme	B-KP
disease	I-KP
,	O
seemingly	O
triggered	O
by	O
the	O
spirochetal	B-KP
infection	I-KP
.	O
	
Thus	O
,	O
these	O
entities	O
should	O
be	O
considered	O
in	O
the	O
differential	O
diagnosis	O
.	O
	
In	O
endemic	B-KP
areas	I-KP
,	O
concomitant	O
positive	O
serologic	O
results	O
for	O
Lyme	B-KP
disease	I-KP
in	O
patients	O
with	O
other	O
inflammatory	O
arthritides	O
can	O
present	O
a	O
diagnostic	O
challenge	O
,	O
since	O
antibody	B-KP
responses	O
to	O
B	B-KP
.	I-KP
burgdorferi	I-KP
following	O
antibiotic-treated	B-KP
Lyme	I-KP
arthritis	I-KP
typically	O
persist	O
for	O
many	O
years	O
.	O
[	O
25	O
]	O
﻿In	O
our	O
experience	O
,	O
some	O
patients	O
do	O
require	O
longer	O
courses	O
of	O
antibiotic	B-KP
therapy	I-KP
for	O
effective	O
treatment	O
of	O
Lyme	B-KP
arthritis	I-KP
.	O
[	O
12	O
]	O
Thus	O
,	O
if	O
there	O
is	O
mild	O
residual	O
joint	O
swelling	O
after	O
a	O
30-day	O
course	O
of	O
oral	B-KP
antibiotics	I-KP
,	O
we	O
repeat	O
the	O
oral	B-KP
antibiotic	I-KP
regimen	O
for	O
another	O
30	O
days	O
.	O
	
However	O
,	O
for	O
patients	O
who	O
continue	O
to	O
have	O
moderate-to-severe	O
joint	O
swelling	O
after	O
a	O
30-day	O
course	O
of	O
oral	B-KP
antibiotics	I-KP
,	O
we	O
treat	O
with	O
IV	B-KP
ceftriaxone	I-KP
,	O
2gm	O
/	O
day.	O
	
Although	O
there	O
is	O
trend	O
toward	O
greater	O
efficacy	O
with	O
4	O
weeks	O
compared	O
with	O
2	O
weeks	O
of	O
antibiotics	B-KP
,	O
there	O
is	O
also	O
a	O
greater	O
frequency	O
of	O
adverse	O
events	O
.	O
[	O
38	O
]	O
Thus	O
,	O
our	O
practice	O
is	O
to	O
prescribe	O
a	O
4-week	O
course	O
of	O
IV	B-KP
therapy	I-KP
,	O
but	O
to	O
monitor	O
the	O
patient	O
closely	O
and	O
to	O
stop	O
the	O
antibiotic	O
if	O
complications	O
occur	O
.	O
	
Even	O
in	O
patients	O
who	O
had	O
minimal	O
or	O
no	O
improvement	O
with	O
oral	B-KP
doxycycline	I-KP
,	O
we	O
typically	O
observe	O
moderate	O
improvement	O
or	O
even	O
complete	O
resolution	O
of	O
arthritis	O
with	O
IV	O
therapy	O
.	O
	
Moreover	O
,	O
even	O
in	O
those	O
with	O
persistent	B-KP
joint	I-KP
inflammation	I-KP
,	O
the	O
synovitis	B-KP
tends	O
to	O
change	O
after	O
IV	B-KP
therapy	I-KP
with	O
decreased	O
size	O
of	O
effusions	O
but	O
continued	O
synovial	B-KP
tissue	I-KP
hypertrophy	I-KP
and	O
inflammation	O
.	O
	
Courses	O
of	O
longer	O
than	O
30	O
days	O
of	O
IV	B-KP
antibiotics	I-KP
seem	O
not	O
to	O
be	O
beneficial	O
and	O
may	O
be	O
associated	O
with	O
a	O
still	O
greater	O
frequency	O
of	O
adverse	O
effect	O
.	O
[	O
39	O
]	O
Additionally	O
,	O
a	O
recent	O
double-blind	O
,	O
randomized	O
,	O
placebo-controlled	O
study	O
of	O
patients	O
in	O
Europe	O
did	O
not	O
find	O
a	O
benefit	O
of	O
additional	O
oral	B-KP
amoxicillin	I-KP
therapy	I-KP
following	O
treatment	O
with	O
IV	B-KP
ceftriaxone	I-KP
.	O
[	O
40	O
]	O
A	O
number	O
of	O
newer	O
oral	O
antibiotics	B-KP
in	O
an	O
FDA	O
approved	O
drug	O
library	O
,	O
including	O
daptomycin	B-KP
,	O
carbomycin	B-KP
,	O
and	O
cefoperazone	B-KP
,	O
have	O
been	O
shown	O
to	O
have	O
marked	O
efficacy	O
against	O
persisting	O
spirochetes	B-KP
in	O
culture	O
,	O
[	O
41	O
]	O
but	O
it	O
is	O
not	O
yet	O
known	O
whether	O
such	O
antibiotics	B-KP
would	O
be	O
effective	O
in	O
patients	O
with	O
Lyme	B-KP
arthritis	I-KP
that	O
is	O
more	O
difficult	O
to	O
treat	O
.	O
	
﻿Arthritis	O
is	O
a	O
late	B-KP
manifestation	I-KP
of	I-KP
Lyme	I-KP
disease	I-KP
,	O
usually	O
beginning	O
months	O
after	O
the	O
tick	O
bite	O
.	O
	
However	O
,	O
a	O
history	O
of	O
erythema	B-KP
migrans	I-KP
or	O
tick	O
bite	O
may	O
be	O
lacking	O
.	O
	
Patients	O
have	O
intermittent	O
or	O
persistent	O
attacks	O
of	O
joint	O
swelling	O
and	O
pain	O
,	O
primarily	O
in	O
one	O
or	O
a	O
few	O
large	O
joints	O
,	O
often	O
the	O
knee	O
,	O
during	O
a	O
period	O
of	O
months	O
to	O
several	O
years	O
,	O
with	O
few	O
systemic	O
manifestations	O
.	O
	
The	O
diagnosis	O
is	O
established	O
by	O
two-tier	B-KP
serologic	I-KP
testing	I-KP
for	O
B	B-KP
.	I-KP
burgdorferi	I-KP
by	O
ELISA	B-KP
and	O
IgG	B-KP
Western	I-KP
blotting	I-KP
,	O
which	O
typically	O
shows	O
strong	O
responses	O
to	O
many	O
spirochetal	B-KP
proteins	I-KP
with	O
many	O
bands	O
present	O
.	O
	
PCR	B-KP
testing	I-KP
of	O
synovial	O
fluid	O
for	O
B	B-KP
.	I-KP
burgdorferi	I-KP
DNA	I-KP
is	O
often	O
positive	O
prior	O
to	O
antibiotic	B-KP
therapy	I-KP
,	O
but	O
the	O
test	O
is	O
not	O
a	O
reliable	O
indicator	O
of	O
spirochetal	B-KP
eradication	I-KP
following	I-KP
antibiotic	I-KP
treatment	I-KP
,	O
since	O
spirochetal	B-KP
DNA	I-KP
may	O
persist	O
after	O
spirochetal	O
killing	O
.	O
	
Initial	O
recommended	O
therapies	O
include	O
a	O
30-day	O
course	O
of	O
oral	B-KP
doxycycline	I-KP
or	O
amoxicillin	B-KP
.	O
	
However	O
,	O
for	O
patients	O
with	O
persistent	O
joint	O
swelling	O
despite	O
oral	B-KP
therapy	I-KP
,	O
IV	B-KP
ceftriaxone	I-KP
for	O
2	O
to	O
4	O
weeks	O
may	O
be	O
needed	O
for	O
successful	O
treatment	O
.	O
	
A	O
small	O
percentage	O
of	O
patients	O
may	O
have	O
persistent	O
arthritis	O
for	O
months	O
or	O
several	O
years	O
after	O
both	O
oral	B-KP
and	I-KP
IV	I-KP
antibiotic	I-KP
therapy	I-KP
,	I-KP
which	O
may	O
be	O
treated	O
successfully	O
with	O
anti-inflammatory	B-KP
agents	I-KP
,	O
DMARDs	B-KP
,	O
or	O
synovectomy	B-KP
.	O
	
The	O
antibody	B-KP
response	O
to	O
B	B-KP
.	I-KP
burgdorferi	I-KP
declines	O
slowly	O
after	O
treatment	O
,	O
but	O
the	O
test	O
typically	O
remains	O
positive	O
for	O
years	O
after	O
therapy	O
.	O
	
﻿Patients	O
were	O
classified	O
as	O
having	O
LM	B-KP
if	O
they	O
met	O
the	O
criteria	O
established	O
by	O
the	O
CDC	O
for	O
Lyme	B-KP
disease	I-KP
(	O
positive	O
serology	O
with	O
Western	O
blot	O
confirmation	O
or	O
erythema	B-KP
migrans	I-KP
observed	O
by	O
a	O
physician	O
)	O
and	O
had	O
meningitis	O
.	O
[	O
1	O
]	O
Criteria	O
for	O
serologic	B-KP
diagnosis	I-KP
were	O
based	O
on	O
published	O
criteria	O
for	O
results	O
from	O
commercial	O
laboratories	O
[	O
8	O
]	O
and	O
our	O
hospital's	O
laboratory	O
.	O
[	O
9	O
]	O
If	O
initial	O
Lyme-serology	B-KP
results	I-KP
were	O
equivocal	O
but	O
follow-up	O
testing	O
was	O
positive	O
,	O
these	O
children	O
were	O
considered	O
to	O
have	O
Lyme	B-KP
disease	I-KP
.	O
	
Patients	O
with	O
meningitis	O
who	O
did	O
not	O
meet	O
CDC	O
criteria	O
for	O
Lyme	B-KP
disease	I-KP
were	O
classified	O
as	O
having	O
AM	B-KP
.	O
The	O
final	O
discharge	O
diagnosis	O
of	O
all	O
patients	O
was	O
extracted	O
from	O
the	O
medical	O
chart	O
.	O
	
Laboratory	O
values	O
(	O
Lyme	B-KP
serology	I-KP
,	O
CSF	B-KP
red	I-KP
blood	I-KP
cell	I-KP
count	I-KP
,	O
CSF	B-KP
WBC	I-KP
,	O
CSF	B-KP
WBC	I-KP
differential	I-KP
,	O
CSF	B-KP
bacterial	I-KP
culture	I-KP
,	O
CSF	B-KP
viral	I-KP
culture	I-KP
,	O
and	O
CSF	B-KP
enterovirus	I-KP
PCR	I-KP
)	O
and	O
demographic	O
information	O
(	O
age	O
,	O
gender	O
,	O
race	O
,	O
and	O
month	O
of	O
presentation	O
)	O
were	O
abstracted	O
electronically	O
from	O
our	O
hospital’s	O
laboratory	O
database	O
.	O
	
Lyme	B-KP
serology	I-KP
was	O
completed	O
by	O
our	O
hospital	O
laboratory	O
using	O
a	O
previously	O
described	O
protocol	O
.	O
[	O
9	O
]	O
Standard	O
techniques	O
were	O
used	O
for	O
CSF	B-KP
bacterial	I-KP
and	I-KP
viral	I-KP
cultures	I-KP
.	O
	
The	O
virology	O
laboratory	O
of	O
the	O
Children's	O
Hospital	O
of	O
Philadelphia	O
(	O
Philadelphia	O
,	O
PA	O
)	O
performed	O
all	O
enterovirus	B-KP
CSF	I-KP
PCR	I-KP
testing	I-KP
.	O
	
﻿Neuroimaging	B-KP
findings	O
are	O
typically	O
unremarkable	O
in	O
Lyme	B-KP
disease	I-KP
.	O
	
Single-photon	B-KP
emission	I-KP
computed	I-KP
tomography	I-KP
scans	I-KP
are	O
more	O
likely	O
to	O
show	O
abnormalities	O
(	O
often	O
with	O
multifocal	O
areas	O
of	O
decreased	O
perfusion	O
in	O
the	O
cortex	B-KP
and	O
subcortical	B-KP
white	I-KP
matter	I-KP
)	O
than	O
magnetic	B-KP
resonance	I-KP
imaging	I-KP
scans	I-KP
are	O
,	O
but	O
single-photon	B-KP
emission	I-KP
computed	I-KP
tomography	I-KP
scans	I-KP
offer	O
little	O
positive	O
or	O
negative	O
predictive	O
value	O
in	O
the	O
diagnosis	O
.	O
[18–20]	O
MRT	O
2-weighted	O
imaging	O
in	O
some	O
cases	O
can	O
reveal	O
white	B-KP
matter	I-KP
lesions	I-KP
,	O
enlarged	B-KP
ventricles	I-KP
,	O
and	O
cortical	B-KP
atrophy	I-KP
;	O
however	O
,	O
these	O
results	O
are	O
nonspecific	O
,	O
and	O
the	O
spirochete	B-KP
does	O
not	O
appear	O
to	O
preferentially	O
settle	O
in	O
certain	O
brain	B-KP
territories	I-KP
(	O
as	O
it	O
does	O
in	O
herpes	O
simplex	O
virus	O
infection	O
)	O
.	O
	
Neuropsychologic	B-KP
testing	I-KP
sometimes	O
confirms	O
objective	O
(	O
often	O
nonspecific	O
)	O
impairments	O
,	O
as	O
is	O
the	O
case	O
with	O
other	O
infectious	O
diseases	O
.	O
[19,21]	O
Electroencephalograms	B-KP
typically	O
lack	O
abnormal	O
findings	O
,	O
except	O
in	O
cases	O
of	O
Lyme	B-KP
disease	I-KP
that	O
present	O
with	O
encephalitis	B-KP
.	O
	
Cerebrospinal	B-KP
fluid	I-KP
(	O
CSF	B-KP
)	O
analysis	O
for	O
Lyme	B-KP
antibodies	I-KP
is	O
not	O
necessary	O
for	O
the	O
diagnosis	O
of	O
Lyme	B-KP
disease	I-KP
even	O
when	O
the	O
nervous	O
system	O
is	O
affected	O
.	O
[	O
22	O
]	O
However	O
,	O
it	O
can	O
be	O
helpful	O
to	O
exclude	O
other	O
,	O
more	O
dangerous	O
,	O
pathogens	O
.	O
	
It	O
is	O
rare	O
to	O
have	O
CSF	B-KP
antibodies	B-KP
without	O
serologic	O
ones	O
,	O
so	O
the	O
absence	O
of	O
serologic	B-KP
antibodies	I-KP
indicates	O
that	O
Lyme	B-KP
disease	I-KP
is	O
not	O
present	O
.	O
	
Likewise	O
,	O
a	O
negative	O
result	O
on	O
CSF	B-KP
antibody	I-KP
test	I-KP
does	O
not	O
exclude	O
central	B-KP
nervous	I-KP
system	I-KP
Lyme	I-KP
disease	I-KP
and	O
a	O
positive	O
CSF	B-KP
antibody	I-KP
test	I-KP
does	O
not	O
establish	O
the	O
presence	O
of	O
Lyme	B-KP
disease	I-KP
(	O
as	O
antibodies	B-KP
can	O
diffuse	O
from	O
the	O
serum	O
to	O
the	O
CSF	B-KP
)	O
.	O
	
﻿In	O
contrast	O
to	O
post-treatment	O
Lyme	B-KP
disease	I-KP
syndrome	I-KP
,	O
chronic	O
Lyme	B-KP
disease	I-KP
is	O
a	O
controversial	O
term	O
that	O
causes	O
considerable	O
confusion	O
owing	O
to	O
lack	O
of	O
a	O
standardized	O
case	O
definition	O
,	O
with	O
some	O
even	O
questioning	O
its	O
existence	O
.	O
	
Ingeneral	O
,	O
it	O
refers	O
to	O
individuals	O
who	O
attribute	O
bodily	O
symptoms	O
to	O
a	O
persistent	B-KP
Lyme	I-KP
infection	I-KP
,	O
irrespective	O
of	O
whether	O
theyhave	O
a	O
history	O
of	O
Lyme	B-KP
disease	I-KP
.	O
	
Multiple	O
patient	O
advocacy	O
groups	O
that	O
have	O
encouraged	O
patients	O
(	O
many	O
of	O
whom	O
had	O
negative	O
results	O
on	O
serologic	B-KP
testing	I-KP
)	O
to	O
think	O
that	O
they	O
have	O
chronic	O
infections	O
have	O
flourished	O
.	O
[	O
32	O
]	O
This	O
may	O
prevent	O
some	O
individuals	O
from	O
seeking	O
a	O
second	O
opinion	O
that	O
may	O
reveal	O
another	O
disorder	O
.	O
	
Some	O
groups	O
have	O
created	O
their	O
own	O
guide	O
lines	O
for	O
the	O
management	O
of	O
chronic	O
Lyme	B-KP
disease	I-KP
.	O
	
Others	O
contend	O
that	O
physicians	O
lack	O
sufficient	O
knowledge	O
about	O
Lyme	B-KP
disease	I-KP
(	O
and	O
are	O
underdiagnosing	O
it	O
)	O
and	O
that	O
assays	O
used	O
to	O
make	O
the	O
diagnosis	O
are	O
not	O
credible	O
.	O
	
﻿The	O
majority	O
of	O
infections	O
can	O
be	O
cured	O
with	O
use	O
of	O
recommended	O
antimicrobials	B-KP
.	O
	
Patients	O
with	O
physician-diagnosed	O
EMcan	B-KP
be	O
treated	O
with	O
oral	B-KP
doxycycline	I-KP
,	O
amoxicillin	B-KP
,	O
or	O
cefuroxime	B-KP
axetil	I-KP
(7,8).	O
	
Patients	O
with	O
other	O
manifestations	O
of	O
Lyme	B-KP
disease	I-KP
are	O
treated	O
with	O
either	O
oral	B-KP
or	I-KP
intravenous	I-KP
antimicrobials	I-KP
(e.g.,	O
ceftriaxone	B-KP
)	O
,	O
depending	O
on	O
the	O
specific	O
clinical	O
condition	O
.	O
	
Measures	O
to	O
prevent	O
Lyme	B-KP
disease	I-KP
and	O
other	O
tickborne	O
infections	O
include	O
avoiding	O
tick-infested	O
areas	O
when	O
possible	O
,	O
using	O
insect	O
repellents	O
containing	O
20%–30%	O
DEET	B-KP
(N,N-diethyl-m-toluamide)	O
on	O
exposed	O
skin	B-KP
and	O
clothing	O
,	O
and	O
performing	O
daily	O
self-examination	O
for	O
ticks	O
(	O
13	O
)	O
.	O
	
Tick	O
abundance	O
can	O
be	O
reduced	O
around	O
private	O
homes	O
and	O
in	O
recreational	O
areas	O
by	O
removing	O
brush	O
and	O
leaf	O
litter	O
,	O
creating	O
a	O
buffer	O
zone	O
of	O
wood	O
chips	O
or	O
gravel	O
between	O
forests	O
and	O
lawn	O
,	O
applying	O
acaricides	O
,	O
and	O
excluding	O
deer	O
(13,14).	O
	
Tickborne	O
illness	O
can	O
be	O
mitigated	O
by	O
prompt	O
and	O
proper	O
tick	O
removal	O
and	O
by	O
recognizing	O
and	O
seeking	O
treatment	O
for	O
early	O
signs	O
of	O
illness	O
(8,15,16).	O
	
A	O
single	O
dose	O
of	O
doxycycline	B-KP
should	O
be	O
considered	O
for	O
prophylaxis	O
of	O
Lyme	B-KP
disease	I-KP
in	O
persons	O
aged	O
>8	O
years	O
who	O
have	O
been	O
bitten	O
by	O
a	O
nymph	O
or	O
adult	O
I	B-KP
.	I-KP
scapularis	I-KP
or	O
I	B-KP
.	I-KP
pacificus	I-KP
tick	I-KP
in	O
an	O
area	O
in	O
which	O
at	O
least	O
20	O
%	O
of	O
ticks	O
are	O
thought	O
to	O
be	O
infected	O
with	O
B	B-KP
.	I-KP
burgdorferi	I-KP
(	O
8	O
)	O
.	O
	
The	O
tick	O
must	O
have	O
been	O
attached	O
for	O
≥	O
36	O
hours	O
and	O
prophylactic	B-KP
antibiotic	I-KP
administered	O
within	O
72	O
hours	O
of	O
tick	O
removal	O
(	O
8	O
)	O
.	O
	
﻿To	O
reduce	O
the	O
risk	O
of	O
tick	O
bites	O
while	O
in	O
the	O
field	O
,	O
the	O
current	O
Department	O
of	O
Defense	O
(	O
DoD	O
)	O
repellent	B-KP
system	I-KP
was	O
adopted	O
in	O
1991.9	O
This	O
system	O
provides	O
specific	O
personal	B-KP
protective	I-KP
measure	I-KP
(	O
PPM	B-KP
)	O
guidelines	O
for	O
use	O
with	O
the	O
military	O
field	O
uniform	O
,	O
which	O
provides	O
barrier	O
and	O
chemical	O
protection	O
against	O
arthropod	B-KP
borne	I-KP
infections	I-KP
.	O
	
However	O
,	O
compliance	O
with	O
these	O
guidelines	O
has	O
been	O
demonstrated	O
to	O
be	O
inadequate	O
,	O
even	O
under	O
conditions	O
of	O
high	O
risk	O
for	O
arthropod-related	B-KP
disease	I-KP
transmission	O
and	O
nuisance	O
bites	O
.	O
	
Although	O
medical	O
threat	O
briefings	O
are	O
commonly	O
given	O
prior	O
to	O
field	O
missions	O
,	O
studies	O
suggest	O
not	O
only	O
that	O
military	O
personnel	O
have	O
poor	O
knowledge	O
of	O
military	O
PPM	B-KP
guidelines	I-KP
,	O
but	O
that	O
command	O
enforcement	O
of	O
military	O
PPM	B-KP
guidelines	I-KP
is	O
low	O
,	O
and	O
that	O
a	O
variety	O
of	O
less	O
effective	O
commercial	O
repellent	O
products	O
are	O
preferred	O
by	O
troops	O
over	O
military-issue	O
products	O
.	O
[10,11]	O
Due	O
to	O
lack	O
of	O
compliance	O
with	O
PPM	B-KP
guidelines	I-KP
,	O
the	O
Armed	O
Forces	O
Epidemiological	O
Board	O
has	O
been	O
evaluating	O
how	O
the	O
ACIP	B-KP
Lyme	I-KP
disease	I-KP
vaccine	I-KP
recommendations	O
should	O
be	O
incorporated	O
into	O
DoD	O
vaccination	O
policies	O
.	O
	
The	O
primary	O
objective	O
of	O
this	O
study	O
was	O
to	O
provide	O
objective	O
epidemiological	B-KP
data	I-KP
that	O
would	O
better	O
characterize	O
the	O
risk	O
for	O
Lyme	B-KP
disease	I-KP
infection	I-KP
among	O
military	O
personnel	O
.	O
	
The	O
seroepidemiology	B-KP
of	O
this	O
pathogen	B-KP
was	O
evaluated	O
in	O
a	O
randomly	O
selected	O
sample	O
of	O
U.S.	O
military	O
personnel	O
,	O
and	O
demographic	O
characteristics	O
and	O
other	O
risk	O
factors	O
for	O
infection	O
were	O
assessed	O
.	O
	
﻿Borrelia	B-KP
burgdorferi	I-KP
(	O
Bb	B-KP
)	O
,	O
a	O
motile	O
,	O
helical	O
gram-negative	O
bacterium	O
,	O
belongs	O
to	O
the	O
spirochete	B-KP
family	I-KP
.	O
	
It	O
stains	O
with	O
Giemsa	O
or	O
special	O
silver	O
stains	O
and	O
can	O
be	O
visualized	O
under	O
phase	O
contrast	O
or	O
dark	O
field	O
microscopy	O
.	O
	
The	O
spirochete	B-KP
,	O
10-	O
to	O
30-pm	O
long	O
and	O
0.2-	O
to	O
0.3-~tm	O
wide	O
,	O
has	O
a	O
central	B-KP
protoplasmic	I-KP
cylinder	I-KP
with	O
7	O
to	O
12	O
attached	O
periplasmic	B-KP
flagella	I-KP
surrounded	O
by	O
an	O
outer	B-KP
cell	I-KP
membrane	I-KP
that	O
is	O
covered	O
by	O
a	O
carbohydrate-containing	B-KP
slime	I-KP
layer	I-KP
.	O
	
Bb	B-KP
contains	O
chromosomal	B-KP
DNA	I-KP
and	O
extrachromosomal	B-KP
double-stranded	I-KP
DNA	I-KP
in	O
the	O
form	O
of	O
distinct	O
supercoiled	B-KP
circular	I-KP
and	I-KP
linear	I-KP
plasmids	I-KP
.	O
	
Both	O
chromosomal	O
and	O
plasmid	B-KP
DNA	I-KP
code	I-KP
for	O
proteins	O
,	O
some	O
of	O
which	O
are	O
not	O
unique	O
to	O
Bb	B-KP
.	O
	
These	O
include	O
p41	B-KP
(	O
flagellin-a	O
protein	O
common	O
to	O
spirochetes	O
)	O
and	O
p58-60	B-KP
,	O
p66	B-KP
,	O
p68	B-KP
,	O
p71	B-KP
,	O
and	O
p73	B-KP
(	O
heat-shock	B-KP
proteins	I-KP
)	O
.	O
	
These	O
conserved	O
but	O
nonspecific	O
borrelia	B-KP
proteins	I-KP
cause	O
serological	B-KP
cross-reactivity	I-KP
,	O
as	O
discussed	O
later	O
.	O
	
Bb-unique	O
proteins	O
include	O
:	O
plasmid-coded	O
outer	B-KP
surface	I-KP
lipoproteins	I-KP
(	O
Osp	B-KP
)	O
31	O
kDa	O
(	O
OspA	B-KP
)	O
;	O
34	O
kDA	O
(	O
OspB	B-KP
)	O
;	O
23	O
kDA	O
(	O
OspC	B-KP
)	O
;	O
newly	O
recognized	O
proteins	O
OspD	B-KP
,	O
OspE	B-KP
,	O
OspF	B-KP
;	O
and	O
p93	B-KP
,	O
a	O
protein	O
that	O
appears	O
to	O
be	O
a	O
protoplasmic	B-KP
cylinder	I-KP
antigen	I-KP
,	O
and	O
p39	B-KP
,	O
a	O
unique	O
lipoprotein	B-KP
.	O
[	O
17	O
]	O
﻿Facial	B-KP
nerve	I-KP
palsy	I-KP
.	O
	
Facial	B-KP
nerve	I-KP
palsy	I-KP
(	O
FNP	B-KP
)	O
,	O
the	O
most	O
frequent	O
neurological	O
complication	O
in	O
children	O
[37,43,53,54,57,61,64,75,76]	O
can	O
be	O
the	O
presenting	O
manifestation	O
of	O
Lyme	B-KP
disease	I-KP
.	O
	
In	O
large	O
series	O
,	O
about	O
one	O
third	O
of	O
patients	O
with	O
Lyme	B-KP
disease-associated	I-KP
FNP	I-KP
report	O
antecedent	O
EM	B-KP
.	O
When	O
a	O
tick	O
bite	O
is	O
recalled	O
or	O
EM	B-KP
occurs	O
on	O
the	O
face	O
or	O
neck	O
,	O
FNP	B-KP
usually	O
affects	O
the	O
same	O
side	O
.	O
	
Bilateral	O
involvement	O
is	O
common	O
,	O
involving	O
6	O
%	O
to	O
37	O
%	O
of	O
patients	O
.	O
[19,53,55-57,75-79]	O
Lyme	B-KP
disease-associated	I-KP
FNP	I-KP
displays	O
a	O
distinct	O
seasonal	O
pattern	O
,	O
from	O
May	O
to	O
November	O
,	O
with	O
peak	O
incidence	O
in	O
the	O
summer	O
months	O
.	O
	
European	O
studies	O
indicate	O
that	O
Lyme	O
neuroborreliosis	O
is	O
the	O
most	O
common	O
cause	O
of	O
FNP	B-KP
in	O
children	O
who	O
live	O
in	O
endemic	B-KP
areas	I-KP
.	O
[14,15,54,59,75,76]	O
Overall	O
,	O
more	O
than	O
one	O
third	O
(	O
34	O
%	O
to	O
43	O
%	O
)	O
of	O
children	O
with	O
FNP	B-KP
were	O
found	O
to	O
have	O
neuroborreliosis	B-KP
as	O
indicated	O
by	O
detection	O
of	O
CSF	B-KP
Bb-specific	I-KP
IgM	I-KP
antibodies	I-KP
.	O
[54,59,75.76]	O
Prospective	O
studies	O
also	O
reveal	O
that	O
the	O
percentage	O
rises	O
to	O
more	O
than	O
50	O
%	O
during	O
the	O
summer	O
months	O
.	O
[59,76]	O
This	O
contrasts	O
with	O
adult	O
studies	O
in	O
which	O
the	O
relative	O
frequency	O
of	O
Lyme	B-KP
disease-associated	O
FNP	B-KP
is	O
estimated	O
to	O
be	O
20	O
%	O
to	O
25	O
%	O
)	O
.	O
	
[14,80]	O
﻿Aseptic	B-KP
meningitis	I-KP
.	O
	
In	O
the	O
absence	O
of	O
EM	B-KP
or	O
FNP	B-KP
,	O
Lyme	B-KP
meningitis	I-KP
may	O
be	O
indistinguishable	O
from	O
aseptic	O
(	O
viral	O
)	O
meningitis	B-KP
.	O
	
In	O
both	O
conditions	O
,	O
patients	O
may	O
have	O
headache	B-KP
,	O
neck	B-KP
stiffness	I-KP
,	O
and	O
fever	B-KP
.	O
	
CSF	B-KP
cell	I-KP
count	I-KP
and	O
chemistries	O
are	O
identical	O
,	O
and	O
both	O
have	O
a	O
seasonal	O
occurrence	O
.	O
	
If	O
meningitis	B-KP
develops	O
in	O
the	O
spring	O
,	O
summer	O
,	O
or	O
fall	O
,	O
and	O
the	O
child	O
lives	O
in	O
or	O
has	O
recently	O
traveled	O
to	O
an	O
endemic	B-KP
area	I-KP
,	O
and	O
Lyme	B-KP
disease	I-KP
is	O
suspected	O
,	O
serum	O
and	O
CSF	B-KP
anti-B	I-KP
,	O
burgdorferi	B-KP
antibodies	I-KP
should	O
be	O
obtained	O
.	O
	
Facial	B-KP
nerve	I-KP
palsy	I-KP
.	O
	
The	O
clinical	O
features	O
of	O
Lyme-associated	B-KP
facial	I-KP
nerve	I-KP
palsy	I-KP
are	O
similar	O
to	O
those	O
of	O
idiopathic	O
Bell's	B-KP
palsy	I-KP
.	O
	
In	O
the	O
absence	O
of	O
EM	B-KP
,	O
Lyme	B-KP
disease	I-KP
should	O
be	O
considered	O
if	O
the	O
child	O
lives	O
in	O
or	O
has	O
recently	O
traveled	O
to	O
an	O
endemic	B-KP
area	I-KP
and	O
the	O
onset	O
of	O
paralysis	O
is	O
in	O
the	O
spring	O
,	O
summer	O
,	O
or	O
fall	O
.	O
	
Anti-B	B-KP
.	I-KP
burgdorferi	I-KP
antibody	B-KP
titers	O
in	O
serum	O
should	O
be	O
obtained	O
.	O
	
If	O
positive	O
,	O
CSF	B-KP
examination	O
to	O
detect	O
occult	B-KP
meningitis	I-KP
is	O
recommended	O
by	O
many	O
.	O
[54,72,75,98]	O
If	O
negative	O
,	O
we	O
repeat	O
serological	B-KP
studies	I-KP
in	O
6	O
to	O
8	O
weeks	O
.	O
	
Optic	B-KP
nerve	I-KP
edema	I-KP
/	O
optic	B-KP
neuritis	I-KP
/	O
increased	O
intracranial	O
pressure	O
.	O
	
The	O
above	O
also	O
applies	O
for	O
the	O
child	O
who	O
has	O
Lyme	B-KP
disease	I-KP
exposure	O
,	O
without	O
a	O
history	O
of	O
EM	B-KP
,	O
and	O
presents	O
with	O
optic	O
neuritis	O
or	O
optic	B-KP
nerve	I-KP
edema	I-KP
with	O
or	O
without	O
other	O
signs	O
of	O
increased	O
intracranial	O
pressure	O
.	O
	
Other	O
causes	O
should	O
be	O
excluded	O
by	O
appropriate	O
studies	O
.	O
	
﻿Lyme	B-KP
disease	I-KP
(	O
LD	B-KP
)	O
is	O
a	O
tick-borne	O
infection	O
caused	O
by	O
the	O
spirochete	B-KP
Borrelia	I-KP
burgdorferi	I-KP
.	O
	
Primary	O
LD	B-KP
commonly	O
presents	O
as	O
a	O
flu-like	O
ifiness	O
in	O
children	O
,	O
sometimes	O
accompanied	O
by	O
the	O
diagnostic	O
rash	O
known	O
as	O
erythema	B-KP
migrans	I-KP
(	O
EM	B-KP
)	O
.	O
	
[	O
1	O
]	O
Rheumatologic	B-KP
,	O
neurologic	B-KP
,	O
dermatologic	B-KP
,	O
or	O
cardiologic	B-KP
manifestations	O
in	O
systemic	O
LD	B-KP
may	O
follow	O
the	O
primary	O
infection	O
by	O
weeks	O
or	O
months	O
,	O
or	O
they	O
may	O
be	O
the	O
initial	O
presentation	O
of	O
LD	B-KP
.	O
A	O
wide	O
variety	O
of	O
neurologic	B-KP
syndromes	I-KP
have	O
been	O
reported	O
in	O
both	O
children	O
and	O
adults	O
with	O
LD	B-KP
,	O
ranging	O
from	O
acute	B-KP
myositis	I-KP
to	O
chronic	B-KP
encephalopathy	I-KP
.	O
	
However	O
,	O
facial	B-KP
palsy	I-KP
and	O
aseptic	B-KP
meningitis	I-KP
are	O
the	O
most	O
commonly	O
reported	O
neurologic	B-KP
manifestations	I-KP
.	O
[	O
2	O
]	O
The	O
nonspecificity	O
of	O
clinical	O
presentations	O
and	O
limitations	O
in	O
laboratory	O
diagnosis	O
complicate	O
the	O
diagnosis	O
of	O
neuroborreliosis	B-KP
.	O
	
While	O
Lyme	B-KP
serology	I-KP
is	O
considered	O
highly	O
sensitive	O
in	O
systemic	B-KP
LD	I-KP
,	O
false	O
positives	O
may	O
be	O
due	O
to	O
asymptomatic	B-KP
seroconversion	I-KP
,	O
antibodies	O
to	O
oral	B-KP
spirochetes	I-KP
,	O
prior	O
infection	O
,	O
or	O
immunologic	O
cross	O
reaction	O
to	O
other	O
pathogens	B-KP
.	O
	
Several	O
authors	O
have	O
emphasized	O
the	O
precedence	O
of	O
clinical	O
criteria	O
for	O
making	O
diagnostic	O
and	O
treatment	O
decisions	O
in	O
patients	O
with	O
suspected	O
LD	O
.	O
[	O
3-5	O
]	O
When	O
new	O
neurologic	O
symptoms	O
appear	O
in	O
concert	O
with	O
other	O
clinical	O
manifestations	O
typical	O
of	O
LD	B-KP
,	O
the	O
diagnosis	O
of	O
neuroborreliosis	B-KP
is	O
usually	O
secure	O
.	O
	
Because	O
individuals	O
with	O
systemic	O
signs	O
of	O
LD	B-KP
are	O
usually	O
seropositive	B-KP
,	O
we	O
reviewed	O
clinical	O
data	O
in	O
seropositive	B-KP
children	O
to	O
determine	O
1	O
)	O
how	O
often	O
the	O
initial	O
clinical	O
evaluation	O
permitted	O
a	O
diagnosis	O
of	O
neuroborreliosis	B-KP
,	O
and	O
2	O
)	O
the	O
range	O
of	O
neurologic	O
signs	O
in	O
children	O
with	O
positive	O
Lyme	B-KP
serology	I-KP
.	O
	
﻿Arthritis	O
is	O
the	O
most	O
common	O
late	O
manifestation	O
of	O
Lyme	B-KP
disease	I-KP
and	O
in	O
one	O
study	O
(	O
7	O
)	O
was	O
documented	O
to	O
occur	O
in	O
60	O
%	O
of	O
patients	O
in	O
whom	O
infection	O
was	O
not	O
treated	O
at	O
earlier	O
stages	O
,	O
usually	O
developing	O
many	O
months	O
(	O
average	O
6	O
months	O
)	O
after	O
infection	O
.	O
	
Most	O
patients	O
present	O
with	O
an	O
oligoarticular	B-KP
inflammatory	I-KP
arthritis	I-KP
affecting	O
1	O
or	O
more	O
large	O
joints	O
,	O
especially	O
the	O
knee	O
[	O
7	O
]	O
(	O
Table	O
2	O
)	O
.	O
	
The	O
arthritis	O
can	O
be	O
migratory	O
,	O
but	O
involvement	O
of	O
5	O
joints	O
is	O
unusual	O
.	O
	
Other	O
signs	O
may	O
include	O
bursitis	B-KP
or	O
tendinitis	B-KP
and	O
temporomandibular	B-KP
joint	I-KP
pain	I-KP
.	O
	
Children	O
often	O
present	O
with	O
more	O
acute	B-KP
arthritis	I-KP
than	O
adults	O
,	O
with	O
fever	O
and	O
elevated	O
peripheral	O
blood	O
and	O
SF	B-KP
white	I-KP
blood	I-KP
cell	I-KP
counts	I-KP
,	O
suggesting	O
septic	B-KP
arthritis	I-KP
[10,11]	O
.	O
	
Alternatively	O
,	O
patients	O
with	O
Lyme	B-KP
arthritis	I-KP
may	O
have	O
no	O
other	O
symptoms	O
of	O
systemic	B-KP
infection	I-KP
and	O
present	O
with	O
a	O
large	O
joint	B-KP
effusion	I-KP
with	O
more	O
stiffness	O
than	O
pain	O
.	O
	
Baker’s	B-KP
cysts	I-KP
can	O
form	O
and	O
rupture	O
.	O
	
Without	O
antibiotic	B-KP
treatment	I-KP
,	O
Lyme	B-KP
arthritis	I-KP
may	O
wax	O
and	O
wane	O
,	O
with	O
an	O
episode	O
of	O
synovitis	B-KP
lasting	O
weeks	O
to	O
months	O
;	O
episodes	O
can	O
decrease	O
in	O
frequency	O
and	O
resolve	O
over	O
time	O
[	O
7	O
]	O
.	O
	
A	O
minority	O
(	O
10	O
%	O
)	O
of	O
patients	O
develop	O
synovitis	B-KP
of	O
a	O
joint	O
that	O
persists	O
despite	O
multiple	O
courses	O
of	O
antibiotics	B-KP
,	O
an	O
entity	O
termed	O
“	O
antibiotic-refractory	B-KP
Lyme	I-KP
arthritis	I-KP
”	O
[	O
7	O
]	O
.	O
	
The	O
genetics	O
of	O
both	O
the	O
host	O
(12,13)	O
and	O
the	O
strain	O
of	O
B	B-KP
burgdorferi	I-KP
causing	O
the	O
infection	O
(	O
14	O
)	O
appear	O
to	O
play	O
a	O
role	O
in	O
determining	O
this	O
outcome	O
,	O
which	O
shares	O
features	O
with	O
other	O
forms	O
of	O
nonseptic	B-KP
inflammatory	I-KP
arthritis	I-KP
(	O
Table	O
2	O
)	O
.	O
	
﻿Patients	O
with	O
Lyme	B-KP
arthritis	I-KP
are	O
initially	O
treated	O
with	O
a	O
4-week	O
course	O
of	O
oral	B-KP
antibiotics	I-KP
.	O
	
Nonsteroidal	B-KP
antiinflammatory	I-KP
drugs	I-KP
are	O
often	O
used	O
to	O
ameliorate	O
symptoms	O
during	O
and	O
after	O
antibiotic	B-KP
treatment	I-KP
.	O
	
Incomplete	O
resolution	O
of	O
arthritis	O
at	O
4	O
weeks	O
has	O
been	O
observed	O
in	O
40	O
%	O
of	O
patients	O
,	O
and	O
an	O
additional	O
course	O
of	O
oral	O
or	O
intravenous	O
antibiotics	O
may	O
be	O
necessary	O
(	O
37	O
)	O
.	O
	
No	O
controlled	O
trials	O
are	O
available	O
to	O
guide	O
the	O
decision	O
regarding	O
whether	O
further	O
antibiotics	B-KP
should	O
be	O
prescribed	O
versus	O
antiinflammatory	O
medications	O
,	O
including	O
intraarticular	B-KP
corticosteroids	I-KP
,	O
to	O
hasten	O
arthritis	O
resolution	O
.	O
	
Arthritis	O
may	O
be	O
considered	O
refractory	O
to	O
antibiotics	O
if	O
it	O
persists	O
for	O
2	O
months	O
after	O
a	O
course	O
of	O
intravenous	B-KP
antibiotics	I-KP
or	O
1	O
month	O
after	O
two	O
4-week	O
courses	O
of	O
oral	B-KP
antibiotics	I-KP
(	O
if	O
parenteral	O
therapy	O
is	O
not	O
possible	O
)	O
and	O
the	O
results	O
of	O
PCR	B-KP
testing	I-KP
of	O
SF	B-KP
are	O
negative	O
for	O
borrelia	B-KP
DNA	I-KP
[	O
37	O
]	O
.	O
	
Antibiotic-refractory	B-KP
Lyme	I-KP
arthritis	I-KP
is	O
not	O
likely	O
due	O
to	O
persistent	O
infection	O
because	O
intraarticular	B-KP
steroids	I-KP
[	O
36	O
]	O
and	O
/	O
or	O
DMARD	B-KP
therapies	I-KP
(	O
hydroxychloroquine	O
,	O
sulfasalazine	O
,	O
or	O
methotrexate	O
)	O
,	O
and	O
rarely	O
TNF	B-KP
antagonists	I-KP
,	O
have	O
been	O
used	O
successfully	O
without	O
signs	O
of	O
recrudescent	O
infection	O
in	O
the	O
joint	O
or	O
elsewhere	O
[	O
35	O
]	O
.	O
	
Synovectomy	B-KP
can	O
be	O
curative	O
if	O
most	O
of	O
the	O
synovial	B-KP
tissue	I-KP
is	O
removed	O
;	O
excised	O
synovial	B-KP
tissue	I-KP
has	O
been	O
uniformly	O
negative	O
for	O
B	B-KP
burgdorferi	I-KP
by	O
PCR	O
and	O
culture	O
[	O
41	O
]	O
.	O
	
﻿The	O
appearance	O
of	O
new	O
or	O
recurrent	O
objective	O
signs	O
of	O
Lyme	B-KP
disease	I-KP
after	O
antibiotic	B-KP
therapy	I-KP
should	O
prompt	O
evaluation	O
for	O
reinfection	O
or	O
incomplete	O
treatment	O
.	O
	
A	O
recent	O
study	O
in	O
which	O
the	O
causative	O
strain	O
of	O
B	B-KP
burgdorferi	I-KP
was	O
cultured	O
from	O
EM	B-KP
lesions	I-KP
showed	O
that	O
recurrent	O
EM	B-KP
after	O
treatment	O
was	O
due	O
to	O
reinfection	O
rather	O
than	O
a	O
relapse	O
of	O
the	O
previously	O
treated	O
infection	O
[	O
46	O
]	O
.	O
	
In	O
25	O
%	O
of	O
patients	O
with	O
EM	B-KP
,	O
clinical	O
disease	O
resolves	O
but	O
fatigue	O
,	O
cognitive	O
problems	O
,	O
or	O
joint	O
and	O
muscle	O
aches	O
persist	O
at	O
3	O
months	O
after	O
treatment	O
;	O
this	O
percentage	O
decreases	O
to	O
10	O
%	O
at	O
6	O
months	O
.	O
	
Posttreatment	B-KP
Lyme	I-KP
disease	I-KP
syndrome	I-KP
(	O
PTLDS	B-KP
)	O
refers	O
to	O
such	O
symptoms	O
that	O
last	O
for	O
6	O
months	O
after	O
a	O
documented	O
episode	O
of	O
Lyme	O
disease	O
and	O
are	O
disabling	O
.	O
	
The	O
frequency	O
with	O
which	O
PTLDS	B-KP
occurs	O
is	O
believed	O
to	O
be	O
substantially	O
below	O
10	O
%	O
.	O
	
PTLDS	B-KP
should	O
not	O
be	O
confused	O
with	O
"	O
chronic	B-KP
Lyme	I-KP
disease	I-KP
.	O
"	O
This	O
name	O
originally	O
referred	O
to	O
late	O
manifestations	O
of	O
the	O
disease	O
,	O
but	O
has	O
been	O
usurped	O
as	O
a	O
label	O
for	O
clinical	O
syndromes	O
that	O
may	O
or	O
may	O
not	O
be	O
associated	O
with	O
previous	O
Lyme	O
borrelia	O
exposure	O
[	O
47	O
]	O
.	O
	
The	O
reasons	O
for	O
persistence	O
of	O
symptoms	O
in	O
some	O
patients	O
after	O
treatment	O
for	O
Lyme	O
disease	O
are	O
not	O
known	O
.	O
	
Theories	O
include	O
residual	O
damage	O
to	O
tissue	O
,	O
slow	O
resolution	O
of	O
the	O
inflammatory	O
state	O
,	O
and	O
/	O
or	O
a	O
form	O
of	O
cytokine-induced	O
sickness	O
behavior	O
due	O
to	O
previously	O
high	O
levels	O
of	O
circulating	O
cytokines	O
.	O
	
Systemic	B-KP
inflammatory	I-KP
cytokines	I-KP
exert	O
adverse	O
effects	O
on	O
neurobehavioral	O
function	O
in	O
other	O
conditions	O
,	O
independent	O
of	O
a	O
central	B-KP
nervous	I-KP
system	I-KP
infection	I-KP
[	O
8	O
]	O
.	O
	
Nonspecific	O
symptoms	O
such	O
as	O
fatigue	O
and	O
pain	O
are	O
common	O
in	O
the	O
general	O
population	O
as	O
well	O
.	O
	
﻿Spirochetes	B-KP
with	O
similar	O
morphology	O
,	O
protein	B-KP
profile	I-KP
and	O
antigenic	B-KP
determinants	I-KP
were	O
detected	O
in	O
Ixodes	B-KP
ricinus	I-KP
ticks	I-KP
from	O
Switzerland	O
and	O
Ixodes	B-KP
pacificus	I-KP
ticks	I-KP
from	O
Oregon	O
[7,16]	O
and	O
subsequently	O
in	O
Ixodes	B-KP
persulcatus	I-KP
ticks	I-KP
in	O
Russia	O
[	O
17	O
]	O
.	O
	
Genotyping	O
subsequently	O
established	O
that	O
Lyme	B-KP
disease	I-KP
in	O
Europe	O
was	O
caused	O
not	O
only	O
by	O
Bb	B-KP
sensu	I-KP
stricto	I-KP
,	I-KP
but	O
also	O
by	O
two	O
genotypically	O
distinct	O
species	O
,	O
which	O
were	O
named	O
Borrelia	B-KP
afzelii	I-KP
and	O
Borrelia	B-KP
garinii	I-KP
and	O
subsumed	O
under	O
the	O
B	B-KP
.	I-KP
burgdorferi	I-KP
sensu	I-KP
lato	I-KP
complex	I-KP
(	O
here	O
Borrelia	O
species	O
abbreviated	O
as	O
Borrelia	B-KP
spp	I-KP
.	O
)	O
,	O
which	O
now	O
contains	O
at	O
least	O
20	O
confirmed	O
or	O
proposed	O
genomic	O
species	O
(	O
see	O
Table	O
1	O
)	O
.	O
	
Of	O
these	O
,	O
Borrelia	B-KP
spielmanii	I-KP
,	O
Borrelia	B-KP
bavariensis	I-KP
,	O
Borrelia	B-KP
bissettii	I-KP
,	O
Borrelia	B-KP
lusitaniae	I-KP
,	O
Borrelia	B-KP
americana	I-KP
,	O
Borrelia	B-KP
andersonii	I-KP
and	O
Borrelia	B-KP
valaisiana	I-KP
also	O
have	O
pathogenic	O
potential	O
(	O
see	O
Table	O
1	O
for	O
the	O
available	O
evidence	O
)	O
.	O
	
Of	O
particular	O
note	O
,	O
it	O
had	O
long	O
been	O
held	O
that	O
Bb	B-KP
is	O
the	O
only	O
species	O
causing	O
Lyme	B-KP
disease	I-KP
in	O
the	O
US	O
,	O
but	O
PCR-based	O
detection	O
of	O
both	O
B	B-KP
.	I-KP
americana	I-KP
and	O
B	B-KP
.	I-KP
andersonii	I-KP
has	O
been	O
reported	O
in	O
blood	B-KP
or	O
skin	B-KP
of	O
a	O
number	O
of	O
US	O
patients	O
,	O
some	O
of	O
them	O
with	O
EM	B-KP
and	O
/	O
or	O
other	O
manifestations	O
of	O
Lyme	B-KP
disease	I-KP
[18,19]	O
.	O
	
In	O
addition	O
,	O
B	B-KP
.	I-KP
bissettii	I-KP
,	O
which	O
has	O
been	O
isolated	O
from	O
the	O
cerebral	B-KP
spinal	I-KP
fluid	I-KP
(	O
CSF	B-KP
)	O
of	O
a	O
European	O
patient	O
with	O
Lyme	B-KP
disease	I-KP
[	O
20	O
]	O
,	O
has	O
also	O
been	O
detected	O
by	O
PCR	B-KP
in	O
serum	O
of	O
three	O
Californian	O
subjects	O
,	O
but	O
details	O
on	O
whether	O
this	O
was	O
associated	O
with	O
any	O
disease	O
manifestations	O
are	O
not	O
available	O
[	O
21	O
]	O
.	O
	
It	O
should	O
be	O
kept	O
in	O
mind	O
,	O
however	O
,	O
that	O
detection	O
by	O
PCR	B-KP
or	O
even	O
isolation	O
by	O
culture	O
of	O
a	O
particular	O
species	O
of	O
Borrelia	B-KP
does	O
not	O
prove	O
its	O
pathogenicity	O
since	O
it	O
is	O
not	O
uncommon	O
for	O
patients	O
to	O
simultaneously	O
harbor	O
two	O
or	O
more	O
species	O
[	O
22e25	O
]	O
.	O
	
While	O
direct	O
PCR	B-KP
of	O
tissue	B-KP
samples	I-KP
appears	O
to	O
be	O
more	O
sensitive	O
than	O
culture-based	B-KP
typing	I-KP
,	O
it	O
does	O
not	O
reliably	O
amplify	O
all	O
strains	O
identified	O
by	O
culture	O
[	O
26	O
]	O
.	O
	
﻿It	O
is	O
customary	O
to	O
divide	O
Lyme	B-KP
disease	I-KP
into	O
three	O
stages	O
.	O
	
The	O
“	O
primary	B-KP
lesion	I-KP
”	O
or	O
early	O
localized	O
stage	O
occurs	O
at	O
the	O
site	O
of	O
Borrelia	B-KP
inoculation	I-KP
.	O
	
The	O
infection	O
is	O
manifest	O
as	O
erythema	B-KP
migrans	I-KP
(	O
migrating	O
redness	O
)	O
,	O
an	O
erythematous	B-KP
papule	I-KP
that	O
expands	O
centrifugally	O
over	O
days	O
to	O
become	O
a	O
plaque	B-KP
,	O
with	O
or	O
without	O
central	O
clearing	O
(	O
Fig	O
.	O
	
2	O
)	O
.	O
	
With	O
the	O
development	O
of	O
EM	B-KP
,	O
the	O
patient	O
may	O
also	O
have	O
constitutional	O
symptoms	O
such	O
as	O
fever	B-KP
,	O
malaise	B-KP
,	O
and	O
headache	B-KP
.	O
	
The	O
skin	B-KP
lesion	I-KP
may	O
have	O
localized	O
pain	O
or	O
pruritus	B-KP
,	O
and	O
regional	B-KP
lymphadenopathy	I-KP
may	O
develop	O
.	O
	
In	O
~	O
20	O
%	O
of	O
untreated	O
subjects	O
,	O
this	O
early	O
stage	O
with	O
EM	B-KP
remains	O
the	O
only	O
manifestation	O
of	O
Lyme	B-KP
disease	I-KP
.	O
	
In	O
the	O
first	O
few	O
weeks	O
after	O
infection	O
,	O
spirochetes	B-KP
can	O
be	O
cultured	O
from	O
blood	O
of	O
up	O
to	O
45	O
%	O
of	O
American	O
patients	O
,	O
indicating	O
that	O
they	O
disseminate	O
via	O
the	O
bloodstream	O
to	O
other	O
tissues	O
[	O
101-103	O
]	O
.	O
	
Note	O
,	O
however	O
,	O
that	O
culture	O
isolation	O
from	O
blood	O
is	O
much	O
less	O
frequently	O
achieved	O
in	O
European	O
patients	O
(0.7-7.7%)	O
[	O
104-106	O
]	O
,	O
possibly	O
suggesting	O
other	O
routes	O
of	O
dissemination	O
.	O
	
The	O
“	O
secondary	B-KP
lesions	I-KP
”	O
of	O
Borrelia	B-KP
infection	I-KP
,	O
the	O
early	O
disseminated	O
stage	O
,	O
comprises	O
multiple	O
EM	B-KP
lesions	I-KP
,	O
widespread	O
erythematous	B-KP
plaques	I-KP
that	O
are	O
smaller	O
but	O
morphologically	O
similar	O
to	O
the	O
initial	O
lesion	B-KP
.	O
	
The	O
early	O
disseminated	O
stage	O
may	O
also	O
be	O
associated	O
with	O
Lyme	B-KP
neuroborreliosis	I-KP
(	O
LNB	B-KP
)	O
,	O
and	O
carditis	B-KP
.	O
	
European	O
patients	O
may	O
also	O
develop	O
a	O
skin	B-KP
lesion	I-KP
called	O
borrelial	B-KP
lymphocytoma	I-KP
during	O
this	O
stage	O
(	O
Fig	O
.	O
	
3	O
)	O
.	O
	
The	O
“	O
tertiary	B-KP
skin	I-KP
lesion	I-KP
”	O
of	O
this	O
infection	O
,	O
identified	O
for	O
decades	O
before	O
the	O
association	O
with	O
Borreliawas	B-KP
known	O
,	O
is	O
acrodermatitis	B-KP
chronic	I-KP
atrophicans	I-KP
,	O
a	O
focal	O
area	O
of	O
atrophic	B-KP
skin	I-KP
usually	O
involving	O
an	O
extremity	O
.	O
	
Acordermatitis	B-KP
chronica	I-KP
atrophicans	I-KP
(	O
ACA	B-KP
)	O
is	O
primarily	O
found	O
in	O
Europe	O
,	O
and	O
is	O
most	O
commonly	O
associated	O
with	O
the	O
late	O
disseminated	O
stage	O
,	O
which	O
can	O
also	O
include	O
late	O
neurological	O
manifestations	O
.	O
	
Although	O
LA	B-KP
can	O
occur	O
during	O
the	O
early	O
disseminated	O
stage	O
,	O
it	O
is	O
more	O
commonly	O
observed	O
during	O
the	O
late	O
disseminated	O
stage	O
.	O
	
﻿If	O
left	O
untreated	O
,	O
~	O
60	O
%	O
of	O
patients	O
with	O
EM	B-KP
develop	O
brief	O
recurrent	O
episodes	O
of	O
arthritis	O
,	O
often	O
preceded	O
and	O
accompanied	O
by	O
arthralgias	B-KP
and	O
myalgias	B-KP
[	O
4	O
]	O
.	O
	
Patients	O
with	O
EM	B-KP
would	O
be	O
treated	O
with	O
antibiotics	B-KP
today	O
and	O
would	O
rarely	O
if	O
ever	O
develop	O
arthritis	O
.	O
	
Therefore	O
,	O
patients	O
diagnosed	O
with	O
LA	B-KP
today	O
must	O
come	O
mainly	O
from	O
those	O
subsets	O
of	O
patients	O
whose	O
EM	B-KP
goes	O
unnoticed	O
or	O
undiagnosed	O
or	O
who	O
do	O
not	O
develop	O
EM	B-KP
or	O
any	O
other	O
typical	O
early	O
manifestations	O
of	O
Lyme	B-KP
disease	I-KP
.	O
	
Approximately	O
one-fourth	O
of	O
adults	O
and	O
between	O
16	O
and	O
37	O
%	O
of	O
children	O
with	O
LA	B-KP
recall	O
a	O
tick	O
bite	O
[172,247-250]	O
.	O
	
More	O
importantly	O
,	O
almost	O
30	O
%	O
of	O
adults	O
give	O
a	O
history	O
of	O
EM	B-KP
[	O
172	O
]	O
,	O
even	O
in	O
case	O
series	O
recruited	O
within	O
the	O
last	O
decade	O
[	O
247	O
]	O
,	O
while	O
the	O
proportion	O
in	O
children	O
has	O
ranged	O
between	O
4	O
and	O
18	O
%	O
in	O
recent	O
cohorts	O
[247,251,252]	O
.	O
	
According	O
to	O
data	O
from	O
a	O
large	O
vaccine	B-KP
trial	I-KP
in	O
which	O
participants	O
were	O
very	O
closely	O
monitored	O
,	O
16	O
%	O
of	O
patients	O
with	O
Bb	B-KP
infection	I-KP
have	O
only	O
systemic	B-KP
symptoms	I-KP
(	O
primarily	O
headaches	B-KP
and	O
arthralgias	B-KP
)	O
[	O
253	O
]	O
that	O
would	O
not	O
likely	O
be	O
recognized	O
as	O
Lyme	B-KP
disease	I-KP
by	O
the	O
patient	O
or	O
the	O
treating	O
physician	O
.	O
	
An	O
additional	O
7e11	O
%	O
of	O
the	O
participants	O
show	O
asymptomatic	B-KP
seroconversion	I-KP
[68,254]	O
.	O
	
Even	O
under	O
the	O
worst-case	O
scenario	O
that	O
60	O
%	O
of	O
these	O
two	O
patient	O
subgroups	O
develop	O
LA	B-KP
,	O
one	O
would	O
expect	O
arthritis	O
to	O
be	O
the	O
presenting	O
manifestation	O
in	O
only	O
~	O
16	O
%	O
of	O
patients	O
with	O
Lyme	B-KP
disease	I-KP
in	O
the	O
US	O
.	O
Rather	O
surprisingly	O
,	O
patients	O
with	O
LA	B-KP
continue	O
to	O
represent	O
~	O
30	O
%	O
of	O
the	O
cases	O
reported	O
to	O
the	O
CDC	O
[	O
159	O
]	O
.	O
	
In	O
contrast	O
,	O
the	O
observed	O
rate	O
in	O
large	O
case	O
series	O
of	O
adults	O
and	O
children	O
with	O
Lyme	B-KP
disease	I-KP
has	O
been	O
6	O
%	O
[160,161]	O
.	O
	
In	O
other	O
words	O
,	O
the	O
majority	O
of	O
cases	O
of	O
LA	O
in	O
the	O
US	O
would	O
seem	O
to	O
be	O
preventable	O
.	O
	
LA	O
constitutes	O
4e8	O
%	O
of	O
cases	O
of	O
Lyme	O
borreliosis	I-KP
in	O
European	O
epidemiological	O
studies	O
[51,53,54,163],	O
although	O
the	O
results	O
of	O
a	O
Swedish	O
study	O
suggest	O
that	O
LA	O
may	O
be	O
underdiagnosed	O
[	O
255	O
]	O
.	O
	
While	O
Lyme	O
disease	I-KP
overall	O
affects	O
men	O
and	O
women	O
with	O
similar	O
frequency	O
,	O
up	O
to	O
75	O
%	O
of	O
adults	O
and	O
70	O
%	O
of	O
children	O
with	O
LA	O
are	O
male	O
not	O
only	O
in	O
the	O
US	O
[4,247,248,250,251,256-258],	O
but	O
also	O
in	O
Europe	O
[170,172,249,259,260]	O
.	O
	
﻿The	O
manifestations	O
of	O
Lyme	B-KP
disease	I-KP
are	O
routinely	O
treated	O
with	O
antibiotics	B-KP
;	O
therapy	O
hastens	O
the	O
resolution	O
and	O
largely	O
prevents	O
the	O
development	O
of	O
other	O
disease	O
manifestations	O
.	O
	
The	O
classes	O
of	O
antibiotics	B-KP
that	O
have	O
shown	O
the	O
greatest	O
effectiveness	O
against	O
Borrelia	B-KP
spirochetes	I-KP
is	O
b-lactams	B-KP
(	O
in	O
particular	O
cephalosporins	O
)	O
tetracyclines	B-KP
and	O
,	O
to	O
a	O
lesser	O
extent	O
,	O
macrolides	B-KP
.	O
	
The	O
best	O
treatment	O
approach	O
,	O
in	O
particular	O
the	O
duration	O
of	O
therapy	O
,	O
is	O
a	O
matter	O
of	O
ongoing	O
debate	O
.	O
	
It	O
is	O
quite	O
evident	O
that	O
not	O
all	O
patients	O
,	O
and	O
most	O
certainly	O
not	O
all	O
species	O
or	O
strains	O
of	O
Borrelia	B-KP
[	O
113	O
]	O
respond	O
equally	O
to	O
the	O
antibiotics	B-KP
most	O
commonly	O
used	O
in	O
the	O
treatment	O
of	O
Lyme	B-KP
disease	I-KP
.	O
	
Based	O
on	O
the	O
available	O
evidence	O
from	O
randomized	B-KP
controlled	I-KP
trials	I-KP
(	O
RCTs	B-KP
)	O
,	O
treatment	O
recommendations	O
have	O
been	O
published	O
by	O
the	O
Infectious	O
Diseases	O
Society	O
of	O
America	O
(	O
IDSA	O
)	O
[	O
221	O
]	O
,	O
the	O
American	O
Academy	O
of	O
Pediatrics	O
[	O
271	O
]	O
,	O
and	O
by	O
a	O
variety	O
of	O
national	O
and	O
supranational	O
associations	O
in	O
Europe	O
[203,272]	O
(www.eucalb.com).	O
	
As	O
the	O
comparison	O
between	O
the	O
guidelines	O
published	O
by	O
the	O
IDSA	O
and	O
the	O
EUCALB	O
in	O
Table	O
4	O
illustrates	O
,	O
the	O
approaches	O
to	O
therapy	O
are	O
largely	O
similar	O
on	O
both	O
sides	O
of	O
the	O
Atlantic	O
,	O
but	O
there	O
are	O
some	O
minor	O
differences	O
in	O
the	O
recommended	O
dosage	O
and	O
treatment	O
duration	O
.	O
	
Note	O
that	O
the	O
International	O
Lyme	O
and	O
Associated	O
Diseases	O
Society	O
has	O
also	O
published	O
guidelines	O
for	O
the	O
management	O
of	O
Lyme	B-KP
disease	I-KP
[	O
273	O
]	O
.	O
	
These	O
advocate	O
more	O
aggressive	O
and	O
longer	O
treatment	O
courses	O
for	O
patients	O
with	O
persistent	O
symptoms	O
or	O
refractory	O
disease	O
,	O
but	O
much	O
of	O
the	O
terminology	O
is	O
poorly	O
defined	O
and	O
the	O
cited	O
“	O
evidence	O
”	O
is	O
largely	O
restricted	O
to	O
older	O
studies	O
that	O
support	O
such	O
an	O
approach	O
and	O
ignores	O
much	O
of	O
the	O
other	O
available	O
evidence	O
.	O
	
The	O
results	O
of	O
several	O
RCTs	B-KP
and	O
a	O
large	O
retrospective	O
study	O
do	O
not	O
show	O
any	O
benefit	O
in	O
extending	O
the	O
duration	O
of	O
treatment	O
with	O
doxycycline	B-KP
from	O
10	O
days	O
to	O
15	O
or	O
20	O
days	O
in	O
patients	O
with	O
EM	B-KP
[	O
274-276	O
]	O
.	O
	
Retrospectively	O
obtained	O
data	O
suggest	O
a	O
similar	O
conclusion	O
for	O
amoxicillin	B-KP
[	O
276	O
]	O
.	O
	
In	O
another	O
double-blind	O
RCT	B-KP
,	O
treatment	O
of	O
patients	O
with	O
disseminated	O
Lyme	B-KP
borreliosis	I-KP
with	O
a	O
3-week	O
course	O
of	O
i.v.	O
	
ceftriaxone	O
followed	O
by	O
100	O
days	O
of	O
amoxicillin	B-KP
did	O
not	O
improve	O
the	O
outcome	O
compared	O
to	O
a	O
3-week	O
course	O
of	O
ceftriaxone	B-KP
alone	O
[	O
277	O
]	O
.	O
	
These	O
findings	O
do	O
not	O
exclude	O
that	O
some	O
patients	O
may	O
benefit	O
from	O
longer	O
or	O
more	O
aggressive	O
therapy	O
,	O
but	O
the	O
risk-benefit	O
ratio	O
has	O
to	O
be	O
carefully	O
weighed	O
for	O
each	O
individual	O
patient	O
.	O
	
